Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Postoperative inflammation" patented technology

About Postoperative Ocular Inflammation: Postoperative Ocular Inflammation is defined as inflammation of the eye as result of a surgical intervention. The following list of medications are in some way related to, or used in the treatment of this condition.

Medical nanofiber reinforced hydrophilic composite material as well as preparation method and application thereof

The invention discloses a medical nanofiber reinforced hydrophilic composite material as well as a preparation method and application thereof. The composite material is prepared from a hydrophilic basis material and nano staple fibers, wherein the nano staple fibers are maintained in crystal morphology and are uniformly dispersed in the hydrophilic basis material; the mass percent of the nano staple fibers in the composite material is 1 to 30 percent; the nano staple fibers have the diameters of 200nm to 800nm and the lengths of 10mu m to 100mu m; according to the preparation method of the medical nanofiber reinforced composite material, which is provided by the invention, the technological design is peculiar; the nano staple fibers are uniformly dispersed in the basis material by utilizing the solubility difference of the basis material and the nano staple fibers; the multicellular spongy composite material is obtained by adopting a freeze drying method; the composite material keeps the respective advantages of two materials; defects are complementary; the composite material which is excellent in mechanical performance, good in biocompatibility and good in biodegradability is obtained, and the medical nanofiber reinforced hydrophilic composite material is moderate in degradation cycle, cannot cause a postoperative inflammation and the postoperative risk of adhesion, is more suitable for clinical demand.
Owner:SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES

Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof

The invention discloses an application of pirfenidone in the preparation of medicaments for controlling proliferative diseases after an ophthalmologic operation and eye drops thereof. According to the invention, pirfenidone is prepared into the eye drops. Experiments show that pirfenidone has good stability and good ocular tissue permeability, can inhibit HLECs migration and propagation, and has no cytotoxicity to HLECs within the action range (0-1mg / ml). With pirfenidone being within the range of 0-1%, the eye drops are continuously applied on eyes within a month with safety and with no obvious toxic and side effect. Pirfenidone can be used to delay the generation of PCO after the rabbit corneal Phaco operation, reduce HLECs propagation and minimize the shield of PCO to an optical region. In addition, there is no obvious ocular surface injury or postoperative inflammation aggravation and severe adverse reaction after PFD is applied in the rabbit corneal Phaco operation. Therefore, pirfenidone can be used to control proliferative diseases after an ophthalmologic operation, especially posterior capsule opacification generated after a cataract surgery.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Ophthalmic compositions and methods of use

The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid. The present invention also provides a method for using such composition to treat an eye disorder such as a dry eye syndrome; ocular graft-versus-host-disease; ocular rosacea; allergic conjunctivitis; autoimmune ocular surface disease; thygeson's superficial punctuate keratopathy; herpes zoster keratitis; Stevens-Johnson syndrome; keratitis; conjunctivitis; blepharitis; blepharochalasis; conjunctivochalasis; blepharoconjunctivitis; blepharokeratoconjunctivitis; post-operative inflammation or pain from ocular surgery; scleritis; episcleritis; anterior uveitis; iritis; cyclitis; ocular surface vascular disorder; ulcerative keratitis; photokeratitis; dacryocystitis; eyelid disorder; congenital alacrima; xerophthalmia; dacryoadenitis; vernal keratoconjunctivitis; pinguecula; and / or ocular surface disorder induced by chemical burns, thermal burns, or physical insult to the ocular surface.
Owner:OCUGEN INC

Methods for treatment of postoperative inflammation with reduced intraocular pressure

Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.
Owner:SUN PHARMA GLOBAL FZE

Intraocular lens with concentric ring pattern and surface modified by degradable drug sustained-release coating and preparation method of intraocular lens with concentric ring pattern and surface modified by degradable drug sustained-release coating

The invention relates to the field of medical implant materials and instrument surface modification in the ophthalmology department, in particular to a foldable intraocular lens with a concentric ring pattern, drug sustained release function and a surface modified by a degradable drug sustained-release coating, and a preparation method of the foldable intraocular lens. The degradable drug sustained-release coating with the concentric ring pattern is formed by spin-coating a sustained-release drug composition on the surface of the intraocular lens, and the sustained-release drug composition comprises a degradable polymer, a drug and an organic solvent. The spin-coating technology is applied, the drug sustained-release coating has the special concentric ring pattern with the thin center and the thick periphery, the influence on refraction, stability and foldability of the intraocular lens is small, and the drug sustained-release coating is not prone to falling off and can be stably attached to the surface of the intraocular lens, through drug reasonable selection, the intraocular lens can be used for effectively preventing various common complications after cataract phacoemulsification surgery, such as posterior capsular opacity, intraocular inflammation and other postoperative inflammatory reactions, and the surgery effect is guaranteed.
Owner:WENZHOU MEDICAL UNIV

Slow release type linezolid preparation for eyes as well as preparation method and application thereof

InactiveCN108553407ASignificant and long-lasting effectGood intraocular penetrationAntibacterial agentsOrganic active ingredientsOcular bioavailabilityDisease
The invention relates to a slow release type linezolid preparation for eyes as well as a preparation method and application thereof. The slow release type linezolid preparation is prepared from the following components: linezolid, polycarbophil, disodium edetate, an auxiliary material and water for injection, wherein the mass ratio of linezolid to polycarbophil to disodium edetate is 1 to (0.5 to2) to (0.05 to 0.2); the mass percent of linezolid is 0.1 percent to 1 percent. Dosage form of the preparation comprise eye drops, eye ointment and eye gel. The slow release type linezolid preparationhas a remarkable and long-lasting pharmaceutical effect, has good intraocular penetrability and relatively high intraocular bioavailability and has the advantages of strong penetration force, strongtargeting effect and small toxic and side effects; the slow release type linezolid preparation is suitable for treating and preventing outer eye and anterior segment diseases caused by non-infection inflammations and postoperative inflammations, and has good antibacterial and inflammation-diminishing effects, small irritation and high safety; raw materials are easy to obtain, a preparation processis simple and the cost is low; industrialized large-scale production can be realized and the economic benefit is remarkable.
Owner:广州君博医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products